New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 27, 2014
07:22 EDTLBIO, ARGS, AVXT, GALE, GNBTMaidstone Life Sciences to hold a conference
4th Annual Cancer Immunotherapy: A Long Awaited Reality Conference is being held in New York on March 27.
News For LBIO;ARGS;AVXT;GALE;GNBT From The Last 14 Days
Check below for free stories on LBIO;ARGS;AVXT;GALE;GNBT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 22, 2014
15:46 EDTGALEGalena in-license of Zuplenz makes sense, says Piper Jaffray
Subscribe for More Information
09:55 EDTGALEGalena 'stands little chance' of improving Zuplenz sales, TheStreet says
After Galena BioPharma entered into a license agreement with MonoSol Rx for Zuplenz, TheStreet's Adam Feuerstein predicted that the company "stands little chance of delivering higher sales of Zuplenz than its previous marketer," calling the drug one that "no one wants" and "something to promote while waiting for the phase III study of NeuVax in breast cancer to inevitably fail." Reference Link
07:21 EDTGALEGalena enters into licensing agreement with MonoSol Rx
MonoSol Rx announced that it has licensed Zuplenz to Galena Biopharma. Zuplenz is an oral soluble film, or OSF, for the prevention of chemotherapy-induced, radiotherapy-induced, and postoperative nausea and vomiting. The licensing agreement includes an undisclosed upfront payment from Galena, as well as double digit royalty payments from sales of Zuplenz. Zuplenz is the first oral soluble lingual film product approved by the FDA as a prescription medication, based on MonoSol Rx's proprietary PharmFilm technology.
July 21, 2014
16:35 EDTARGSArgos Therapeutics presents results from trial of AGS-004
Argos Therapeutics announced that the company has presented data from its research involving AGS-004, the company's investigational fully personalized immunotherapy for HIV, at the International AIDS Society Towards a Cure Symposium that was held at the Victoria University City Convention Centre in Melbourne, Australia. Results were presented by Dr. Irina Tcherepanova, Argos' director of molecular biology, in a poster titled "Impact of RNA loaded Dendritic cell immunotherapy on HIV sequence Evolution in Chronic HIV Subjects Undergoing ATI," on Saturday, July 19, from 4:35 6:00 PM. Previously, Argos reported results of a Phase 2a clinical trial designed to assess the impact of AGS-004 during a 12-week ART analytical treatment interruption in chronic HIV-1-infected subjects. In this follow-up sub-study, results presented revealed how viral protein sequences evolve in response to AGS-004-induced immune pressure, and that viral load control was associated with low viral sequence divergence. "To our knowledge this is the first report associating HIV antigen sequence divergence in response to autologous therapeutic immunization with durability of VL control. These results further illustrate the potential for AGS-004 and we are looking forward to additional research milestones later this year," said Charles Nicolette, Argos' chief scientific officer and VP of research and development. This is the first analysis aimed at understanding the effects of AGS-004-induced immune pressure in HIV subjects on viral evolution and diversity. AGS-004 is being further evaluated in a double-blind placebo-controlled phase 2b clinical trial and the company plans to announce initial results from this trial in the coming months.
July 17, 2014
08:51 EDTLBIOLion Biotechnologies deal increases visibility, says Roth Capital
After Lion Biotechnologies (LBIO) and Immunocore entered into an agreement to co-discover and co-develop novel T-cell based cancer therapies. Roth Capital thinks the deal increases the visibility for T-cell therapies and is positive for Lion Biotechnologies. The firm sees the deal as an indication that large drug companies remain interested in the T-cell based immunotherapy space, and it thinks that Lion is well-positioned in the space. The firm reiterates a $20 price target and Buy rating on Lion.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use